Skip to content

Randomised trial, 2020

Does Echium amoenum herb help reduce PMS symptoms?

Yes. Women taking Echium amoenum showed much greater reduction in PMS symptom scores than placebo over 2 months, with mean scores dropping from 35.3 to 16.1 compared to 31.0 to 28.3 for placebo.

Moderate study design 84 women aged 20 to 35 with PMS in college (69 completed)

What they did

Researchers recruited 120 college women and enrolled 84 eligible women aged 20 to 35 with PMS. They randomly assigned women to 450mg Echium amoenum capsules three times daily or placebo, taken from day 21 of the menstrual cycle until day 3 of the next cycle for 2 cycles. 69 women completed the study.

What they found

Mean symptom scores in the Echium amoenum group dropped from 35.3 at baseline to 16.1 after 2 months (P less than or equal to 0.001), while placebo group scores went from 31.0 to 28.3 (P=0.09). After adjusting for age and body mass index, the herb group scores were 6.2 and 11.6 at first and second follow-ups.

What it means for you

Echium amoenum herb significantly reduced PMS symptoms compared to placebo. 15 women dropped out of the study, which could bias results. Findings are from college students in one country and may not apply to other populations.

450mg x3

daily Echium amoenum dose

2 months

duration (2 menstrual cycles)

69

women who completed study

About the study

Original title
Effectiveness of Echium amoenum on premenstrual syndrome: a randomized, double-blind, controlled trial
Authors
Farahmand M, Khalili D, Ramezani Tehrani F et al.
Journal
BMC complementary medicine and therapies
Year
2020
Study design
Randomised trial
Participants
84
What was tested
Echium amoenum 450mg capsules, three times daily for 2 menstrual cycles
Open access
Yes
Original abstract

Background: The present study aimed to evaluate the effect of Echium amoenum (EA) on the severity of premenstrual syndrome (PMS) in comparison with placebo. Methods: The present study was a randomized double-blind controlled clinical trial. A checklist questionnaire was completed by 120, 18 to 35-year-old, college students. And then, 84 eligible women (20 to 35 years old) were enrolled in the trial; they were randomly assigned to two groups of intervention (EA) and control (placebo), with 42 participants in each group. Participants in the intervention group received 450 mg capsules of EA per day (three times a day) from the 21st day of their menstrual cycle until the 3rd day of their next cycle for two consecutive cycles. The severity of PMS was measured and ranked using the premenstrual symptoms screening tool (PSST). The generalized estimating equation was used to compare the total score of the severity of PMS between the two groups. Results: Sixty-nine women with regular menstrual cycles suffering from PMS completed the study. The mean scores of the symptoms in the EA group were 35.3 and 16.1 (P ≤ 0.001) at baseline and after 2 months, respectively, while the mean scores of the symptoms in the placebo group were 31.0 and 28.3 (P = 0.09) at baseline and after 2 months, respectively. The evaluation of the first and the second follow-ups in the intervention group showed that, after being adjusted for age and body mass index (P ≤ 0.001), the mean scores of the premenstrual syndrome, using GEE analysis, have decreased to 6.2 and 11.6, respectively. Conclusion: Based on the results, in comparison with the placebo group, EA was found to be more effective in improving the symptoms of PMS, and is highly recommended for treatment of this syndrome. Trial registration: IRCT2015110822779N3 ; Registration date: 2015-11-27.

Reproduced under CC-BY.

Topics